ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

FDA Approves Evista for Breast Cancer Risk Reduction.

September 14, 2007

Cancer Control Grows Up Fast As It Moves To Meet Mandate, Take Over Big Part Of NCI Budget

March 15, 1974

The Cancer Letter Provides Full Text Of Publications To University Of Kentucky.

October 19, 2001

In Brief: Administration “Streamlining” Accomplished; DCCR contract Merit Review In Open Session

February 24, 1978

Austria Has highest Cancer Rate, Little NCI Support

June 17, 1977

New Organ Systems Concept Flow Discussed

October 18, 1985